1. Scrip
  2. >>Therapy Areas

Blow To Roche Growth Prospects As TIGIT Lung Cancer Trial Fails

Cancer Combination Fails In Phase III

 
• By Andrew McConaghie

Failure of the tiragolumab plus Tecentriq combination in first line NSCLC patients is a blow to Roche’s immunotherapy aspirations, and its long-term growth strategy.

Roche_Logo_Glass
Tiragolumab had been expected to generate its own peak sales of 2.5bn, and boost those of Tecentriq too. • Source: Alamy

Roche has suffered a major setback in its goal to lead in a new class of cancer immunotherapies, with the surprise failure of its anti-TIGIT tiragolumab in non-small cell lung cancer.

The results have also damaged the firm’s long-term growth prospects, which depend on it finding new cancer therapies to replace

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.